Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). (January 2017)

• Record Type: Journal Article
• Authors: Almeida, Antonio; Fenaux, Pierre; List, Alan F.; Raza, Azra; Platzbecker, Uwe; Santini, Valeria
• Is Part Of: Leukemia research. Volume 52(2017:Jan.)
• Page Start: 50
• Page End: 57
• Publication Date: 2017-01
• Subjects: Myelodysplastic syndromes -- Non-del(5q) -- Anemia -- Red blood cell transfusion dependence -- Treatment; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2016.11.008
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: Primary goal of LR-MDS therapy is to reduce the impact of chronic RBC transfusions. Few treatment options are available after ESA failure. Recent insights have led to a better understanding of the disease heterogeneity. There is a need for a more individualized approach to therapy. Many new treatment options are being explored that may alter the course of the disease. Abstract: Patients with lower-risk myelodysplastic syndromes (MDS) are affected primarily by symptoms of chronic anemia and fatigue rather than progression to acute myeloid leukemia. Severe thrombocytopenia, although less common in lower-risk MDS, is associated with increased risk of bleeding. For anemic patients, the principal aim of treatment is to improve anemia and decrease red blood cell transfusions. For transfusion-dependent patients with lower-risk MDS without chromosome 5q deletion [non-del(5q) MDS], there are limited effective treatments. Erythropoiesis-stimulating agents (ESAs) are generally first-line therapy, yielding frequent responses with a median duration of 18–24 months. Immunosuppressive therapy or allogeneic stem cell transplantation are restricted to select patients. New strategies for ESA-refractory or relapsed patients include lenalidomide, alone or in combination with ESAs; oral azacitidine; and new molecules such as the activin receptor type II ligand traps luspatercept and sotatercept. In thrombocytopenic patients, thrombopoietin receptor agonists are under evaluation. While trials to evaluate these treatment strategies are underway, efforts are needed to optimize therapies through better patient selection and response prediction as well as integrating molecular and genetic data into clinical practice. We provide an overview of current treatment approaches for lower-risk non-del(5q) MDS and explore promising directions for future research.